230 related articles for article (PubMed ID: 27581208)
1. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
de Jong PH; Hazes JM; Buisman LR; Barendregt PJ; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
Rheumatology (Oxford); 2016 Dec; 55(12):2138-2147. PubMed ID: 27581208
[TBL] [Abstract][Full Text] [Related]
2. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
de Jong PH; Hazes JM; Han HK; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; van Schaeybroeck B; de Sonnaville PB; van Krugten MV; Luime JJ; Weel AE
Ann Rheum Dis; 2014 Jul; 73(7):1331-9. PubMed ID: 24788619
[TBL] [Abstract][Full Text] [Related]
3. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
de Jong PH; Hazes JM; Barendregt PJ; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
Ann Rheum Dis; 2013 Jan; 72(1):72-8. PubMed ID: 22679301
[TBL] [Abstract][Full Text] [Related]
4. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
5. Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients.
Nathalie LM; Mulligen VE; Maria WAEA; Wilhelmina HJM; Pieter JPH;
Rheumatology (Oxford); 2021 Dec; 60(12):5765-5774. PubMed ID: 33725091
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
[TBL] [Abstract][Full Text] [Related]
8. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
9. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
[TBL] [Abstract][Full Text] [Related]
10. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.
Tosh JC; Wailoo AJ; Scott DL; Deighton CM
J Rheumatol; 2011 Aug; 38(8):1593-600. PubMed ID: 21572149
[TBL] [Abstract][Full Text] [Related]
12. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.
Wong JB; Singh G; Kavanaugh A
Am J Med; 2002 Oct; 113(5):400-8. PubMed ID: 12401535
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis.
Jalal H; O'Dell JR; Bridges SL; Cofield S; Curtis JR; Mikuls TR; Moreland LW; Michaud K
Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1751-1757. PubMed ID: 27015606
[TBL] [Abstract][Full Text] [Related]
14. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
[TBL] [Abstract][Full Text] [Related]
15. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Foster RH
Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
Vanier A; Mariette X; Tubach F; Fautrel B;
Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
[TBL] [Abstract][Full Text] [Related]
17. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
Stephens S; Botteman MF; Cifaldi MA; van Hout BA
BMJ Open; 2015 Jun; 5(6):e006560. PubMed ID: 26059521
[TBL] [Abstract][Full Text] [Related]
18. Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.
van Mulligen E; Weel AE; Kuijper TM; Denissen NHAM; Gerards AH; de Jager MH; Lam-Tse WK; Hazes JM; van der Helm-van Mil A; de Jong PHP; Luime JJ
Ann Rheum Dis; 2020 Dec; 79(12):1550-1556. PubMed ID: 32907801
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Eriksson JK; Karlsson JA; Bratt J; Petersson IF; van Vollenhoven RF; Ernestam S; Geborek P; Neovius M
Ann Rheum Dis; 2015 Jun; 74(6):1094-101. PubMed ID: 24737786
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
Davies A; Cifaldi MA; Segurado OG; Weisman MH
J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
